Eclipse Surgical Announces First Quarter Financial Results Conference Call Date

Apr 12, 2001, 01:00 ET from Eclipse Surgical Technologies

    SUNNYVALE, Calif., April 12 /PRNewswire/ -- Eclipse Surgical Technologies
 (Nasdaq:   ESTI), a leading medical device company specializing in cardiac
 angiogenesis, today announced plans to release its first quarter financial
 results before the market opens on Wednesday, April 18, 2001, and to host a
 conference call to be broadcast live on the Internet at 11:30am EDT (Eastern)
 that same day.  Those interested in the listening to the live webcast of the
 Eclipse conference call may do so over the Internet by going to
 www.streetfusion.com, or www.eclipsesurg.com.  An online webcast replay of the
 call will also be accessible immediately following the live broadcast for
 seven days at www.streetfusion.com.
 
     About Eclipse Surgical
     Eclipse Surgical Technologies is a leading medical device company
 specializing in cardiac angiogenesis.  The Company currently manufactures and
 markets the Eclipse TMR 2000, a solid-state laser system, as well as the
 Eclipse SoloGrip III, a surgical handpiece with built-in laser fiberoptics.
 Eclipse products are currently installed in over 250 leading hospitals and
 medical centers throughout the U.S.  TMR is a laser heart treatment in which
 one-millimeter channels are created in the heart muscle and are believed to
 stimulate the growth of new blood vessels (angiogenesis).  TMR has been shown
 to reduce angina and improve the quality of life for patients suffering with
 coronary artery disease.
 
     For more information on the Company and its products, please visit the
 Eclipse website at www.eclipsesurg.com.  For additional investor relations
 information visit the Allen & Caron Inc Web site at www.allencaron.com.
 
     The forward-looking statements in this news release related to any
 expected clinical benefits of its products and the adoption of the Company's
 technology and products are based on current expectations and beliefs and are
 subject to numerous risks and uncertainties that could cause actual results to
 differ materially.  Other factors that could cause Eclipse's actual results to
 differ materially include the company's ability to: successfully introduce and
 sell new products, to obtain adequate financing, to obtain regulatory
 approvals and market acceptance of current and future products, as well as
 additional risk factors, as discussed in the "Risk Factors" section of
 Eclipse's Annual Report on Form 10-K for the year ended December 31, 1999, and
 Eclipse's quarterly reports on Form 10-Q and Eclipse's other recent SEC
 filings.  Eclipse disclaims any obligation to update any forward-looking
 statements as a result of developments occurring after the date of this press
 release.
 
 

SOURCE Eclipse Surgical Technologies
    SUNNYVALE, Calif., April 12 /PRNewswire/ -- Eclipse Surgical Technologies
 (Nasdaq:   ESTI), a leading medical device company specializing in cardiac
 angiogenesis, today announced plans to release its first quarter financial
 results before the market opens on Wednesday, April 18, 2001, and to host a
 conference call to be broadcast live on the Internet at 11:30am EDT (Eastern)
 that same day.  Those interested in the listening to the live webcast of the
 Eclipse conference call may do so over the Internet by going to
 www.streetfusion.com, or www.eclipsesurg.com.  An online webcast replay of the
 call will also be accessible immediately following the live broadcast for
 seven days at www.streetfusion.com.
 
     About Eclipse Surgical
     Eclipse Surgical Technologies is a leading medical device company
 specializing in cardiac angiogenesis.  The Company currently manufactures and
 markets the Eclipse TMR 2000, a solid-state laser system, as well as the
 Eclipse SoloGrip III, a surgical handpiece with built-in laser fiberoptics.
 Eclipse products are currently installed in over 250 leading hospitals and
 medical centers throughout the U.S.  TMR is a laser heart treatment in which
 one-millimeter channels are created in the heart muscle and are believed to
 stimulate the growth of new blood vessels (angiogenesis).  TMR has been shown
 to reduce angina and improve the quality of life for patients suffering with
 coronary artery disease.
 
     For more information on the Company and its products, please visit the
 Eclipse website at www.eclipsesurg.com.  For additional investor relations
 information visit the Allen & Caron Inc Web site at www.allencaron.com.
 
     The forward-looking statements in this news release related to any
 expected clinical benefits of its products and the adoption of the Company's
 technology and products are based on current expectations and beliefs and are
 subject to numerous risks and uncertainties that could cause actual results to
 differ materially.  Other factors that could cause Eclipse's actual results to
 differ materially include the company's ability to: successfully introduce and
 sell new products, to obtain adequate financing, to obtain regulatory
 approvals and market acceptance of current and future products, as well as
 additional risk factors, as discussed in the "Risk Factors" section of
 Eclipse's Annual Report on Form 10-K for the year ended December 31, 1999, and
 Eclipse's quarterly reports on Form 10-Q and Eclipse's other recent SEC
 filings.  Eclipse disclaims any obligation to update any forward-looking
 statements as a result of developments occurring after the date of this press
 release.
 
 SOURCE  Eclipse Surgical Technologies